GlaxoSmithKline ((GSK)), GlaxoSmithKline plc (UK) ((GB:GSK)) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
GlaxoSmithKline (GSK) is conducting a clinical study titled ‘A Phase 2, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study (TRANSFORM) to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF).’ The study aims to assess the safety and effectiveness of the new drug GSK3915393 in treating IPF, a chronic lung disease that causes scarring and breathing difficulties.
The intervention being tested is GSK3915393, a drug intended to treat IPF. Participants in the study will receive either GSK3915393 or a placebo to evaluate the drug’s efficacy and safety.
The study uses a randomized, parallel assignment model with quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are unaware of the treatment allocations. The primary purpose of the study is treatment-focused.
The study began on April 4, 2024, with the primary completion and estimated completion dates yet to be announced. The last update was submitted on July 1, 2025, indicating ongoing progress.
This study could significantly impact GSK’s stock performance and investor sentiment, especially if GSK3915393 proves effective. The IPF treatment market is competitive, and a successful outcome could position GSK favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.